{
    "nctId": "NCT00499291",
    "briefTitle": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors",
    "officialTitle": "Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors",
    "overallStatus": "WITHDRAWN",
    "conditions": "Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Inter-individual pharmacokinetic variability",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Patients must have an incurable advanced or refractory tumor amenable to treatment with paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)\n\n  * Per the National Comprehensive Cancer Network, the following cancer sites have been shown to be responsive to taxane therapy:\n\n    * Prostate cancer\n    * Breast cancer\n    * Non-small cell lung cancer\n    * Bladder cancer\n    * Head and neck cancer\n    * Oral cancer\n    * Cervical cancer\n    * Ovarian cancer\n    * Endometrial cancer\n    * Esophageal cancer\n    * Gastric cancer\n    * Germ cell tumors\n    * Tumors of unknown primary\n    * Soft tissue sarcomas\n    * Small cell lung cancer\n    * Testicular cancer\n    * Upper genitourinary tract cancers\n\nPATIENT CHARACTERISTICS:\n\n* Patients must have performance status 0-2 by the ECOG scale\n* Absolute neutrophil count \u2265 1,500/\u03bcL\n* Platelet count \u2265 100,000/\u03bcL\n* Hemoglobin \u2265 9 g/dL\n* Bilirubin \u2264 institutional upper limit of normal (ULN)\n* ALT and AST \u2264 2.5 x ULN\n* Alkaline phosphatase \u2264 2.5 x ULN (if bone metastasis is present in the absence of liver metastasis, alkaline phosphatase must be \u2264 5 x ULN)\n* Creatinine \u2264 1.5 x ULN\n* Patients must not have baseline sensory neuropathy \u2265 grade 2\n* Women must not be pregnant or breastfeeding\n* Negative blood or urine pregnancy test\n* Women of childbearing potential and sexually active males must agree to use an accepted and effective method of contraception\n\nPRIOR CONCURRENT THERAPY:\n\n* Prior treatment is allowed, which may include prior taxane therapy\n\n  * If patient has had prior therapy(ies), s/he must have received last treatment \u2265 28 days prior to registration\n* Patients must not be receiving colony stimulating factors (CSFs)\n\n  * Previous CSFs must have been discontinued \\> 14 days prior to registration\n* Patients must not be receiving concomitant treatment with any of the following (prior use is allowed, but must have been discontinued \u2265 28 days prior to registration):\n\n  * Phenytoin\n  * Carbamazepine\n  * Barbiturates\n  * Rifampicin\n  * Phenobarbital\n  * Hypericum perforatum (St. John's wort)\n  * Ketoconazole",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}